بدائل البحث:
larger decrease » marked decrease (توسيع البحث)
large decrease » marked decrease (توسيع البحث), large increases (توسيع البحث), large degree (توسيع البحث)
laser decrease » linear decrease (توسيع البحث), water decreases (توسيع البحث), teer decrease (توسيع البحث)
_ larger » _ large (توسيع البحث), _ largest (توسيع البحث), a large (توسيع البحث)
c large » _ large (توسيع البحث), a large (توسيع البحث), b large (توسيع البحث)
larger decrease » marked decrease (توسيع البحث)
large decrease » marked decrease (توسيع البحث), large increases (توسيع البحث), large degree (توسيع البحث)
laser decrease » linear decrease (توسيع البحث), water decreases (توسيع البحث), teer decrease (توسيع البحث)
_ larger » _ large (توسيع البحث), _ largest (توسيع البحث), a large (توسيع البحث)
c large » _ large (توسيع البحث), a large (توسيع البحث), b large (توسيع البحث)
-
1
The introduction of mutualisms into assembled communities increases their connectance and complexity while decreasing their richness.
منشور في 2025"…(C) Mutualism also promotes an increase in network connectance when introduced into assembled communities, while stopping mutualistic interactions from entering an assembled system slowly decreases it. …"
-
2
HSF2 reduced the decrease in the MMP in Caco-2 cells, which were observed by laser confocal microscopy.
منشور في 2025"…All the data in this study was presented as mean ± SEM.</p>…"
-
3
-
4
ECoG timescales decrease during spatial attention.
منشور في 2025"…Bottom: timescales significantly decrease during covert attention relative to the attend-out condition (two locations: <i>p</i> = 0.0244; four locations: <i>p</i> < 0.0001; mean ± SEM; whiskers indicate maximum and minimum; dots correspond to individual electrodes). …"
-
5
-
6
-
7
-
8
-
9
-
10
-
11
-
12
-
13
-
14
Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.
منشور في 2025الموضوعات: -
15
-
16
Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.
منشور في 2025الموضوعات: -
17
Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.
منشور في 2025الموضوعات: -
18
-
19
Baseline patient characteristics across neutralizing monoclonal antibody trials.
منشور في 2025الموضوعات: -
20